Andrew Saleh, MD
Sports Medicine · San Diego, CANPI 1699015529
Payments from drug & device makers
Across 241 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Kowa Pharmaceuticals America, Inc.$490
- GSK$416
- Amarin Pharma, Inc.$322
- Lilly USA, LLC$272
- Novartis$265
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,26896%
- Education$60%
- Gifts$1994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $1,551 |
| Kowa Pharmaceuticals America, Inc. | 26 | $490 |
| GSK | 19 | $416 |
| Amarin Pharma, Inc. | 17 | $322 |
| Lilly USA, LLC | 12 | $272 |
| Novartis | 17 | $265 |
| Harmony Biosciences LLC | 6 | $233 |
| Pfizer | 11 | $215 |
| Welch Allyn | 1 | $199 |
| Novo Nordisk | 10 | $193 |
| AbbVie(2 entities) | 6 | $129 |
| Eisai Inc. | 7 | $118 |
| Exact Sciences | 4 | $100 |
| Seqirus USA Inc | 5 | $97 |
| Philips North America LLC | 3 | $92 |
| Gilead | 3 | $83 |
| Abbott | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 4 | $70 |
| Bausch Health US, LLC | 4 | $60 |
| Amgen | 3 | $59 |
| Sanofi Pasteur Inc. | 2 | $46 |
| Boston Scientific | 2 | $39 |
| Phadia US Inc. | 2 | $38 |
| IBSA Pharma Inc. | 2 | $37 |
| Edwards Lifesciences | 1 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 4 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Ortho-clinical Diagnostics, Inc. | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,473 in reported general payments places this provider in the 60th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $44,216 |
| EliquisApixaban | 42 | $34,658 |
| JardianceEmpagliflozin | 25 | $34,179 |
| FarxigaDapagliflozin Propanediol | 31 | $24,434 |
| RybelsusSemaglutide | 16 | $17,487 |
| TrulicityDulaglutide | 16 | $14,606 |
| Citalopram HbrCitalopram Hydrobromide | 29 | $5,182 |
| Atorvastatin Calcium | 251 | $2,418 |
| Levothyroxine Sodium | 203 | $2,262 |
| Rosuvastatin Calcium | 160 | $2,097 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $1,946 |
| Testosterone Cypionate | 31 | $1,734 |
| Tramadol Hcl | 86 | $1,600 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $1,543 |
| Tamsulosin Hcl | 97 | $1,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $193 | $61,70254 claims |
| PfizerEliquis | $215 | $34,65842 claims |
| AstraZenecaFarxiga | $1,551 | $24,43431 claims |
| Lilly USA, LLCTrulicity | $272 | $14,60616 claims |
| AbbVieSynthroid | $129 | $95432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 662 sports medicine providers in California.
Other sports medicine in San Diego
- Okechukwu AnakwenzeSan Diego$623K
- Tal DavidSan Diego$523K
- Michelle LookSan Diego$225K
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Seth ShermanStanford$1.8M
- Michael FreehillStanford$1.7M
- Deryk JonesSan Carlos$1.6M
- Allan MishraMenlo Park$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.